MEDICAL DIAGNOSTIC DEVICE
20230050412 · 2023-02-16
Assignee
Inventors
Cpc classification
G01N33/5008
PHYSICS
C12N15/635
CHEMISTRY; METALLURGY
International classification
Abstract
The present invention relates to a medical diagnostic device with a cellular biosensor which detects urea and uric acid by means of a synthetic genetic circuit essentially consisting of transcriptional regulator and bio-sensing module.
Claims
1-36. (canceled)
37. A medical diagnostic device characterized in that it comprises cellular biosensors performing diagnosis of urea and uric acid; and it is used for diagnosis of various diseases such as routine blood analysis and monitoring biomarkers about kidney health in the medical field.
38. A medical diagnostic device according to claim 37, characterized in that it has capability of performing low-cost, quick scanning and characteristic of providing high-specificity and yield, by means of cellular sensors it contains
39. A medical diagnostic device according to claim 37, characterized in that it comprises cellular biosensors that can perform urea detection, uric acid detection, urea and uric acid detection separately, and can detect that urea and uric acid are present in one environment at the same time.
40. A medical diagnostic device according to claim 37, characterized in that biosensors comprise synthetic genetic circuits.
41. A medical diagnostic device according to claim 37, characterized in that it has synthetic genetic circuits which are essentially configured to have transcriptional regulator and bio-sensing module that vary by the component aimed to be detected.
42. A medical diagnostic device according to claim 37, characterized in that it ensures formation of fluorescent signal increase in case of detecting urea and/or uric acid in the environment, and enables to detect this signal increase by fluorescence spectroscopy
43. A medical diagnostic device according to claim 37, characterized in that the uric acid (X) used for detecting uric acid is cloned from uricase operator system in transcriptional regulator HucR (C) and its DNA binding site HucO (E), organism Deinococcus radiodurans for cellular biosensor parts.
44. A medical diagnostic device according to claim 37, characterized in that HucR (C) is generated by promotor proD (A) continuously.
45. A medical diagnostic device according to claim 37, characterized in that synthetic promoter synpHucO (E) consists of HucO (E) operator placed between −35, −10 regions of viral promoter pL.
46. A medical diagnostic device according to claim 37, characterized in that synthetic promoter synpHucO (E) is activated depending on the presence of uric acid because it contains HucO binding site.
47. A medical diagnostic device according to claim 37, characterized in that entry of uric acid into the cell is possible by uric acid transporter (UACT) (H) gene cloned between minimal promotor mproD (G) that is continuously active on low copy plasmid pZS and RBS site (B) and T7 terminator (D) site.
48. A medical diagnostic device according to claim 37, characterized in that the urea (Y) used for diagnosing urea is cloned from transcriptional regulator UreR (J) from cellular biosensor parts and urease specific promoter region (Intergenic Region) (K) used as a promoter that is inducible by urea, urease operon system of Proteus mirabilis organism.
49. A medical diagnostic device according to claim 37, characterized in that a system consisting of all components of independent urea and uric acid detection and processing modules for a cellular biosensor with separate reporter of urea and uric acid—that is used for diagnosing urea (Y) and uric acid (X)—is designed.
50. A medical diagnostic device according to claim 37, characterized in that a synthetic promoter which is active only in the presence of urea and uric acid, is used in the urea and uric acid biosensor with AND-Logic gate used for diagnosing that urea (Y) and uric acid (X) are present in the environment at the same time.
51. A medical diagnostic device according to claim 37, characterized in that cloning a HucO (E) binding site between −35 and −10 regions of a promoter on the urease specific promoter region (K) makes the transcription activation dependent on the presence of both urea and uric acid.
Description
DETAILED DESCRIPTION OF THE INVENTION
[0012] “A Medical Diagnostic Device” realized to fulfil the objective of the present invention is shown in the figures attached, in which:
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027] The inventive medical diagnostic device comprises cellular biosensors performing diagnosis of urea and uric acid; and it is used for diagnosis of various diseases such as routine blood analysis and monitoring biomarkers about kidney health in the medical field. The said medical diagnostic device has capability of performing low-cost, quick scanning and characteristic of providing high-specificity and yield, by means of cellular sensors it contains.
[0028] The inventive medical diagnostic device is configured to comprise cellular biosensors that can perform urea detection, uric acid detection, urea and uric acid detection separately, and can detect that urea and uric acid are present in one environment at the same time. The biosensors included in the medical diagnostic device comprise synthetic genetic circuits. The said synthetic genetic circuits are essentially configured to have transcriptional regulator and bio-sensing module that vary by the component aimed to be detected. Cellular biosensors ensures formation of fluorescent signal increase in case of detecting urea and/or uric acid in the environment, and enables to detect this signal increase by fluorescence spectroscopy.
[0029] In one embodiment of the invention, the uric acid (X) used for detecting uric acid by the medical diagnostic device is cloned from uricase operator system in transcriptional regulator HucR (C) and its DNA binding site HucO (E), organism Deinococcus radiodurans for cellular biosensor parts. HucR (C) controls transcription negatively. DNA binding affinity of HucR (C) decreases by presence of uric acid in the environment and transcription occurs. The genetic circuit created for expression of HucR (C) protein consists of continuously active promoter site proD (A), ribosome binding site (RBS) (B), gene of HucR (C) protein and rrnB T1 transcriptional terminator (13) site. Here, the promoter region is responsible for initiating transcription upon the RNA polymerase binds Onto the plasmid whereas the rrnB T1 transcriptional terminator region (D) is used for terminating the RNA synthesis. The messenger RNA (mRNA) generated after the transcription initiates the translation by binding to the ribosome with the ribosome binding site placed before thereof, and ensures expression of the desired gene as protein. In this system, HucR (C) is generated by promotor proD (A) continuously. Synthetic promoter synpHucO (E) consists of HucO (E) operator placed between −35, −10 regions of viral promoter pL. Synthetic promoter and RBS (B) are cloned before reporter green fluorescent protein (sfGFP) in (F), and after T7 terminator site (D). Synthetic promoter synpHucO (E) is activated depending on the presence of uric acid because it contains HucO binding site. HucR (C) and sfGFP (F) expression modules are placed to pET22b (+) high copy plasmid. Entry of uric acid into the cell is possible by uric acid transporter (UACT) (H) gene cloned between minimal promotor mproD (G) that is continuously active on low copy plasmid pZS and RBS site (B) and T7 terminator (D) site. Lastly, cellular uric acid biosensor generates a GFP signal (I) in case of detecting uric acid in the environment. Schema, charts of time and concentration-dependent fluorescent expression profile of the uric acid biosensor are indicated in the
[0030] In the
[0031] The
[0032] The
[0033] In another embodiment of the invention, the urea (Y) used for diagnosing urea with the medical diagnostic device is cloned from transcriptional regulator UreR (J) from cellular biosensor parts and urease specific promoter region (Intergenic Region) (K) used as a promoter that is inducible by urea, urease operon system of Proteus mirabilis organism. Production of UreR (J) in cells is ensured by cloning ureR (J) gene between mproD promotor (G) and RBS (B) that are continuously active on low copy plasmid pZS and T7 terminator (D). The ureR (J) has characteristics of binding to operator regions on the urease specific promoter region (K) and activating the transcription, when urea is present in the environment. The urease specific promoter region (K), the RBS (B), the reporter protein sfGFP (F) and the rrnb T1 terminator (D) are placed onto the high copy plasmid pZE. Thereby, the amount of urea in the environment can he detected by measuring the fluorescent signal (GFP signal (I)). Schema, charts of time and concentration-dependent fluorescent expression profile of the urea biosensors are indicated in the
[0034] In the schematic view of the urea biosensor in the
[0035] The
[0036] The
[0037] In another embodiment of the invention, a system consisting of all components of independent urea and uric acid detection and processing modules for a cellular biosensor with separate reporter of urea and uric acid—that is used for diagnosing urea (V) and uric acid (X) by the medical diagnostic device—is designed. Genetic circuits of mproD (G)-RBS (B)-ureR (J)-T7 terminator (D) are used for expression of UreR (J) protein respectively and mproD (G)-RBS (B)-UACT (H)-rrnb T1 terminator (D) are used for expression of UACT (H) transporter, on the pZS plasmid respectively. Whereas genetic circuit of prop (A)-RBS (B)-HucR (C)-T7 terminator is cloned onto pZE plasmid for production of HucR (C) protein. The bin-recognition module on the bio-recognition module is designed such that it will generate sfGFP (F) protein as the reporter; whereas the (pUreD-RBS-sfGFP-rrnb T1 terminator), uric acid bio-recognition module is designed such that it will generate mScarlet I (M) reporter protein as the reporter protein (syn pHucO-RBS-mScarlet I- rrnb T1 terminator). Lastly, a GEP signal (green signal) (I) is generated when it is detected that there is urea in the cellular biosensor environment with separate promoter of the urea and the uric acid; and a RFP signal (red signal) (L) is generated when it is detected that there is uric acid. Schema, charts of time and concentration-dependent fluorescent expression profile of the biosensor with separate reporter for urea and uric acid are indicated in the
[0038] The
[0039] The
[0040] The
[0041] The
[0042] The
[0043] In another embodiment of the invention, a synthetic promoter which is active only in the presence of urea and uric acid is used in the urea and uric acid biosensor with AND-Logic gate used for diagnosing that urea (Y) and uric acid (X) are present in the environment at the same time by the medical diagnostic device. Cloning a HucO (E) binding site between −35 and −10 regions of a promoter on the urease specific promoter region (K) makes the transcription activation dependent on the presence of both urea and uric acid. The synthetic AND-Logic gate promoter is cloned before the RBS (B), reporter sfGFP gene (F) and rrnB T1 terminator (D) region. The generated genetic circuit is combined in a single cell by components of other singular urea and uric acid detection, processing modules Genetic circuits of mproD (G)-RBS (B)-ureR (J)-T7 terminator (D) are used for expression of UreR (J) protein respectively and mproD (G)-RBS (B)-UACT (H)-rrnb T1 terminator (D) are used for expression of UACT (H) transporter, on the pZS plasmid respectively. Genetic circuit of proD (A)-RBS (B)-HucR (C)-T7 terminator (D) is cloned onto pZE plasmid for production of HucR (C) protein. Lastly, a GFP signal (I) is generated when it is detected that urea and uric acid are present at the same time in the urea and uric acid biosensor environment with AND-Logic gate. Schema, charts of time and concentration-dependent fluorescent expression profile of the biosensor with AND-Logic gate are indicated in the
[0044] The
[0045] The
[0046] The
[0047] The cell-based biosensor technology included in the inventive medical diagnostic device is developed as a low-cost, quick and user-friendly diagnostic method for measurement in micro environments. Thereby, it can be used for frequent or real-time measurements of urea and uric acid. In this device, biodiagnosis carried out for external stimuli of specific urea and uric acid is provided by synthetic genetic circuits that exhibit bio-recognition and bio-processing functions. In addition, sensors with capability of detecting multi-analytes simultaneously can be used for medical decision-making for complex diseases. Also, all these cell biosensors can be mounted to more complex hybrid devices as sensor interfaces and the result measurement methods can be adapted for a requested status. As a result, diagnosis of urea and uric acid concentrations is important for clinical, food and environmental industries. Therefore, an inexpensive, modular, user-friendly and quick urea/uric acid biodiagnosis device is a requirement with a wide application area.
[0048] Within these basic concepts; it is possible to develop various embodiments of the inventive medical diagnostic device; the invention cannot be limited to examples disclosed herein and it is essentially according to claims.